Double Blind, Placebo Controlled, Escalating Single-dose, Pilot Study to Assess the Safety of THR-18 When Administered to Patients Suffering Acute Ischemic Stroke and Treated With Tissue Plasminogen Activator (tPA).
Phase of Trial: Phase I/II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs THR 18 (Primary)
- Indications Embolism and thrombosis; Stroke
- Focus Adverse reactions
- 09 Dec 2016 This trial was completed in Austria (end date: 2012-07-17), according to European Clinical Trials Database.
- 26 May 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2011-005317-37).
- 18 Jan 2012 Patient enrolment is underway in Israel, with additional sites expected in India, Europe (Spain, Austria, Germany) and the USA, according to a Hadasit Bio-Holdings media release.